Giuseppe Procopio
Sapienza University of Rome
CancerInternal medicineSurgeryOncologyRetrospective cohort studyAbiraterone acetateEnzalutamideChemotherapyRenal cell carcinomaPazopanibSorafenibSunitinibEverolimusNivolumabProstate cancerNephrectomyDocetaxelTargeted therapyPopulationMedicine
342Publications
31H-index
6,206Citations
Publications 355
Newest
#1Alessandra Mosca (University of Eastern Piedmont)H-Index: 15
#2Ugo De GiorgiH-Index: 42
Last. Camillo Porta (UNIPV: University of Pavia)H-Index: 52
view all 12 authors...
Source
Objectives The aim of our study was to collect data about of the outcome of metastatic renal cell carcinoma patients who progressed after immune checkpoint inhibitors in order to enhance data about efficacy and safety of treatment beyond immune-oncology (IO). Materials and methods A total of 162 eligible patients, progressing to IO, were enrolled from 16 Italian referral centers adhering to the Meet-Uro association. Baseline characteristics, outcome data and toxicities were retrospectively colle...
Source
#1Alberto BongiovanniH-Index: 15
#2Flavia FocaH-Index: 15
Last. Toni IbrahimH-Index: 25
view all 17 authors...
Bone metastases (BM) are still the main cause of morbidity in cancer patients because of skeletal-related events (SREs) that reduce quality of life. They have also led to increased social and healthcare costs. At present, data available on BM are insufficient. This was a multicentre prospective observational study of patients with BM from breast cancer (BC) with at least 6 months' follow-up. Information on patients at the first diagnosis of BM, including demographics and characteristics of the p...
Source
#1Roberta Giorgione (UniFI: University of Florence)
#2Daniele Santini (Università Campus Bio-Medico)H-Index: 56
Last. Giandomenico Roviello (UniFI: University of Florence)H-Index: 19
view all 20 authors...
319Background: Nivolumab is approved in the second or further line of treatment for patients with metastatic renal cell carcinoma (mRCC); cabozantinib is approved in a similar setting of patients. ...
Source
#1Giuseppe ProcopioH-Index: 31
#2Alessia MennittoH-Index: 14
Last. Elena VerzoniH-Index: 17
view all 20 authors...
320Background: The multikinase inhibitor cabozantinib (Cabo) is an effective treatment option for metastatic renal cell carcinoma (mRCC). However, data on the optimal sequencing of Cabo and other a...
Source
Source
#1Marco Stellato (Università Campus Bio-Medico)H-Index: 5
#2Daniele Santini (Università Campus Bio-Medico)H-Index: 56
Last. Elena VerzoniH-Index: 17
view all 11 authors...
299Background: Bone is one of the most common site of metastasis occurring in 30% of metastatic renal cell carcinoma (mRCC) patients (pts)3,4. Skeletal metastases from mRCC are usually osteolytic a...
Source
Abstract Background Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib ...
11 CitationsSource
#1Guillermo VelascoH-Index: 47
Last. Laurence Albiges (Université Paris-Saclay)H-Index: 43
view all 17 authors...
BACKGROUND No available data support the potential response of relapsed recurrent renal cell carcinoma (RCC) patients treated with systemic targeted therapies (TT) after completion of adjuvant sunitinib. In this study, we aimed to assess the efficacy and tolerability of rechallenge with sunitinib and other TT in advanced setting. METHODS In this multi-institutional retrospective study, relapsed RCC patients were re-challenged with sunitinib or other systemic TT as first-line therapeutic approach...
Source
#1Melissa Bersanelli (University of Parma)H-Index: 16
#2Diana GiannarelliH-Index: 53
Last. Riccardo DanielliH-Index: 21
view all 10 authors...
We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no. 2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The hypothesis of an effective prophylactic approach to COV...
Source
12345678910
Close Researchers